DBV Technologies（DBV）株式概要DBV Technologies S.A.は臨床段階のバイオ医薬品会社で、皮膚外免疫療法製品の研究開発に従事している。 詳細DBV ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長5/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より95.2%で取引されている 収益は年間64.77%増加すると予測されています リスク分析キャッシュランウェイが1年未満である 過去1年間で株主の希薄化は大幅に進んだ French市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るDBV Community Fair Values Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€3.40656.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-265m58m2016201920222025202620282031Revenue US$57.7mEarnings US$10.8mAdvancedSet Fair ValueView all narrativesFeatured narrative•Pharmaceuticals & Biotech opportunityUnicycive Therapeutics4 months ago author updated this narrativeSTFair Value from stuart_robertsUS$21.5363.5% 割安 内在価値ディスカウントLooking to be second time lucky with a game-changing new productKey Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read full narrative6.4kusers have viewed this narrative18users have liked this narrative0users have commented on this narrative130users have followed this narrativeRead narrativeDBV Technologies S.A. 競合他社ValnevaSymbol: ENXTPA:VLAMarket cap: €464.6mTransgeneSymbol: ENXTPA:TNGMarket cap: €216.4mSensorionSymbol: ENXTPA:ALSENMarket cap: €209.0mEurobio Scientific Société anonymeSymbol: ENXTPA:ALERSMarket cap: €226.5m価格と性能株価の高値、安値、推移の概要DBV Technologies過去の株価現在の株価€3.4052週高値€4.5052週安値€1.30ベータ-0.241ヶ月の変化-6.59%3ヶ月変化-6.35%1年変化90.38%3年間の変化2.53%5年間の変化-67.46%IPOからの変化-62.09%最新ニュースライブニュース • May 06DBV Technologies Prepares VIASKIN Peanut Regulatory Filings With Expanded Cash Position and New Clinical TrialDBV Technologies reported a Q1 2026 net loss of US$47.6 million as it funds development and regulatory work for its VIASKIN Peanut patch. The company plans to submit two Biologics License Applications in 2026 for children aged 4 to 7 years and toddlers aged 1 to 3 years, and to launch a new Phase 2 THRIVE trial in infants aged 6 to 12 months. An amended 10-K/A and related 8-K detailed expanded governance disclosures, a large PIPE financing completed in 2025 to 2026, and new performance-based share units granted to the CEO tied to FDA progress on VIASKIN Peanut. For you as an investor, the picture is of a company spending heavily to move from pure clinical development toward potential commercialization of a single lead program. The widened Q1 2026 loss reflects higher research, development and commercial infrastructure costs, while the cash and cash equivalents position of US$229 million, supported by about US$386.2 million of equity and warrant funding since March 2025, is described as sufficient to fund operations into Q2 2027. That timeline would give DBV a period to progress its regulatory filings and clinical work without an immediate need for more capital, based on current plans. The governance and compensation disclosures matter because they show how leadership is being incentivized. The CEO’s 1,740,000 performance share units vest only if the FDA accepts the VIASKIN Peanut BLAs and if he remains in the role through mid 2028, which aligns management rewards with key regulatory milestones. Investors may want to track the timing and outcome of the planned BLA submissions, the progress of the THRIVE infant study, and any updates on cash usage against the stated funding runway.Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 54% growth forecast for the Biotechs industry in France.お知らせ • May 01DBV Technologies S.A., Annual General Meeting, Jun 03, 2026DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon Franceお知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026Reported Earnings • Mar 29Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 24%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 49% growth forecast for the Biotechs industry in France.Breakeven Date Change • Mar 29Forecast to breakeven in 2028The 5 analysts covering DBV Technologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 20% per year to 2027. The company is expected to make a profit of US$86.5m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.最新情報をもっと見るRecent updatesライブニュース • May 06DBV Technologies Prepares VIASKIN Peanut Regulatory Filings With Expanded Cash Position and New Clinical TrialDBV Technologies reported a Q1 2026 net loss of US$47.6 million as it funds development and regulatory work for its VIASKIN Peanut patch. The company plans to submit two Biologics License Applications in 2026 for children aged 4 to 7 years and toddlers aged 1 to 3 years, and to launch a new Phase 2 THRIVE trial in infants aged 6 to 12 months. An amended 10-K/A and related 8-K detailed expanded governance disclosures, a large PIPE financing completed in 2025 to 2026, and new performance-based share units granted to the CEO tied to FDA progress on VIASKIN Peanut. For you as an investor, the picture is of a company spending heavily to move from pure clinical development toward potential commercialization of a single lead program. The widened Q1 2026 loss reflects higher research, development and commercial infrastructure costs, while the cash and cash equivalents position of US$229 million, supported by about US$386.2 million of equity and warrant funding since March 2025, is described as sufficient to fund operations into Q2 2027. That timeline would give DBV a period to progress its regulatory filings and clinical work without an immediate need for more capital, based on current plans. The governance and compensation disclosures matter because they show how leadership is being incentivized. The CEO’s 1,740,000 performance share units vest only if the FDA accepts the VIASKIN Peanut BLAs and if he remains in the role through mid 2028, which aligns management rewards with key regulatory milestones. Investors may want to track the timing and outcome of the planned BLA submissions, the progress of the THRIVE infant study, and any updates on cash usage against the stated funding runway.Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 54% growth forecast for the Biotechs industry in France.お知らせ • May 01DBV Technologies S.A., Annual General Meeting, Jun 03, 2026DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon Franceお知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026Reported Earnings • Mar 29Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 24%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 49% growth forecast for the Biotechs industry in France.Breakeven Date Change • Mar 29Forecast to breakeven in 2028The 5 analysts covering DBV Technologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 20% per year to 2027. The company is expected to make a profit of US$86.5m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.お知らせ • Mar 02Dbv Technologies Highlights Additional Data from Successful Phase 3 Vitesse Study At the Aaaai 2026 Annual MeetingDBV Technologies announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV's VIASKIN®? Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years. The VITESSE study met its primary endpoint whereby VIASKIN®?Peanut demonstrated a statistically significant treatment effect (pp. The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period. These results not only support the VIASKIN®? peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population.Price Target Changed • Dec 22Price target increased by 116% to €3.29Up from €1.52, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €3.43. Stock is up 446% over the past year. The company is forecast to post a net loss per share of US$1.05 next year compared to a net loss per share of US$1.17 last year.Major Estimate Revision • Dec 17Consensus revenue estimates decrease by 10%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$7.00m to US$6.26m. EPS estimate unchanged from -US$1.05 per share at last update. Biotechs industry in France expected to see average net income growth of 34% next year. Consensus price target of €1.56 unchanged from last update. Share price rose 11% to €3.68 over the past week.分析記事 • Dec 09Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, DBV Technologies...Major Estimate Revision • Nov 07Consensus revenue estimates decrease by 14%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$7.78m to US$6.69m. EPS estimate increased from -US$1.27 to -US$1.05 per share. Biotechs industry in France expected to see average net income growth of 25% next year. Consensus price target up from €1.52 to €1.56. Share price fell 5.5% to €2.48 over the past week.お知らせ • Nov 04DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial, Effective November 3, 2025DBV Technologies announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin(R) Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year. Kevin Trapp is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical industry. Before rejoining DBV, Kevin served as a consultant to the Company in his most recent role as Managing Director at Biotech Value Advisors (BVA) where he advised biotechnology boards of directors and executive leadership with product strategy, launch planning, and business evaluation. He built his career at Bristol-Myers Squibb (BMS), where he held roles of increasing responsibility across finance, sales, marketing, and general management. During his time at BMS, he managed a ~$4 billion U.S. specialty and primary care portfolio and was a key stakeholder in the planning and subsequent launches of more than 10 products and indications - including Abilify(R), Atripla(R), Reyataz(R), Orencia(R), and Daklinza(R). Mr. Trapp earned a bachelor's degree from the University of Connecticut School of Business and completed the General Management Program from the European Centre for Executive Development (CEDEP) at INSEAD.New Risk • Oct 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$98m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$98m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$81m net loss in 3 years).お知らせ • Sep 19DBV Technologies Announces Resignation of Daniel Soland as a Member of its Board of Directors, Effective September 18, 2025DBV Technologies announced the resignation of Daniel Soland, as a member of its Board of Directors, effective September 18, 2025.お知らせ • Sep 06DBV Technologies S.A. has filed a Follow-on Equity Offering in the amount of $150 million.DBV Technologies S.A. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Transaction Features: At the Market OfferingMajor Estimate Revision • Aug 13Consensus EPS estimates upgraded to US$0.86 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -US$1.17 to -US$0.86 per share. Revenue forecast steady at US$4.03m. Biotechs industry in France expected to see average net income growth of 7.2% next year. Consensus price target of €1.52 unchanged from last update. Share price was steady at €1.69 over the past week.Major Estimate Revision • Aug 05Consensus revenue estimates increase by 33%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$2.98m to US$3.98m. EPS estimate unchanged from -US$1.17 at last update. Biotechs industry in France expected to see average net income growth of 7.2% next year. Consensus price target of €1.52 unchanged from last update. Share price fell 4.6% to €1.63 over the past week.Reported Earnings • Jul 30Second quarter 2025 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2024)Second quarter 2025 results: US$0.31 loss per share. Net loss: US$41.9m (loss widened 26% from 2Q 2024). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in France.お知らせ • Jul 23DBV Technologies S.A. Announces Executive ChangesDBV Technologies S.A. announced the appointment of James Briggs as its Chief Human Resources Officer, succeeding Caroline Daniere. An experienced human capital executive, James will lead key initiatives as DBV transitions from a development-stage biotechnology company to a potential commercial organization. Mr. Briggs will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. Most recently, Mr. Briggs served as Partner at East Bay Human Capital, a human resources consulting firm specializing in human capital strategy, change management, and organizational design. Previously, he held several executive roles, including Chief Executive Officer at MNG Health, where he led the successful turnaround and sale of the healthcare technology company. He also served as Chief Human Resources Officer at multiple organizations, including Ciox Health and Ikaria Inc. Mr. Briggs holds a Master's degree in Human Relations and a Bachelor's degree in Communications from the University of Illinois at Urbana-Champaign. He is a certified Senior Professional in Human Resources (SPHR) and a Six Sigma Green Belt.Price Target Changed • Jul 01Price target decreased by 38% to €1.52Down from €2.46, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €1.56. Stock is up 96% over the past year. The company is forecast to post a net loss per share of US$1.17 next year compared to a net loss per share of US$1.17 last year.Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jun 26DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 - 3 Years OldDBV Technologies provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin®? Peanut patch 250 mg in peanut-allergic children ages 1 - 3 years old. COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 - 90 study centers across the U.S., Canada, Australia, UK and Europe. COMFORT Toddlers is a Phase 3 double-blind, placebo-controlled (DBPC) safety study designed to supplement the safety and efficacy data from the completed Phase 3 EPITOPE study in the same population. The study duration will be six months followed by an optional 18-month open-label treatment phase, to generate up to 24 or 18 months of active treatment with the Viaskin Peanut patch for participants randomized to the active or placebo groups, respectively.お知らせ • May 06DBV Technologies S.A., Annual General Meeting, Jun 11, 2025DBV Technologies S.A., Annual General Meeting, Jun 11, 2025. Location: 107 avenue de la republique 92320 chatillon, Franceお知らせ • Apr 01DBV Technologies S.A. announced delayed annual 10-K filingOn 03/31/2025, DBV Technologies S.A. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Reported Earnings • Mar 24Full year 2024 earnings released: US$1.17 loss per share (vs US$0.77 loss in FY 2023)Full year 2024 results: US$1.17 loss per share (further deteriorated from US$0.77 loss in FY 2023). Net loss: US$113.9m (loss widened 57% from FY 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.分析記事 • Jan 10Revenues Not Telling The Story For DBV Technologies S.A. (EPA:DBV) After Shares Rise 76%DBV Technologies S.A. ( EPA:DBV ) shareholders have had their patience rewarded with a 76% share price jump in the last...New Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$109m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$115m net loss in 3 years). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Market cap is less than US$100m (€67.0m market cap, or US$68.9m).お知らせ • Dec 17DBV Technologies Regains Compliance with Nasdaq Listing Rule 5550(a)(2)On December 13, 2024, DBV Technologies S.A. (the Company") received a letter from the Listing Qualifications Staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). The Staff determined that for 10 consecutive business days, from November 29, 2024 to December 12, 2024, the closing bid price of the Company's American Depositary Shares has been at $1.00 per share or greater.お知らせ • Nov 12DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain ComplianceDBV Technologies S.A. announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to five (5) ordinary shares (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about November 29, 2024 (the “Effective Date”). For the Company’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-five reverse ADS split and is intended to enable the Company to regain compliance with the Nasdaq minimum bid price requirement.Reported Earnings • Nov 08Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023)Third quarter 2024 results: US$0.32 loss per share (further deteriorated from US$0.17 loss in 3Q 2023). Revenue: US$1.07m (down 55% from 3Q 2023). Net loss: US$30.4m (loss widened 82% from 3Q 2023). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 31% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.分析記事 • Oct 24DBV Technologies S.A.'s (EPA:DBV) 41% Share Price Surge Not Quite Adding UpDBV Technologies S.A. ( EPA:DBV ) shareholders would be excited to see that the share price has had a great month...New Risk • Oct 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 5.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$105m free cash flow). Earnings are forecast to decline by an average of 5.2% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$117m net loss in 3 years). Market cap is less than US$100m (€69.6m market cap, or US$75.0m).お知らせ • Oct 23Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and EuropeDBV Technologies announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe. DBV intends to formalize the Accelerated Approval guidance provided by the FDA via submission of a meeting request. Viaskin Peanut Patch in Toddlers 1 – 3 Years. Accelerated Approval Pathway, FDA guidance for Accelerated Approval include three qualifying criteria: 1) that the product treats a serious condition, 2) that the product candidate generally provides a meaningful advantage over available therapies, and 3) that the product candidate demonstrates an effect on an intermediate clinical endpoint that is reasonably likely to predict clinical benefit. FDA confirmed that DBV has met criterion 1 and 2. Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which DBV has agreed to in informal discussions with the FDA. DBV intends to formalize the Accelerated Approval guidance provided by FDA via submission of a meeting request to confirm the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including the third Accelerated Approval criterion regarding the intermediate clinical endpoint. DBV expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved. COMFORT Toddlers DBV is pleased to have aligned with FDA on a wear time collection methodology in COMFORT Toddlers that provides a practical approach for subjects and families, is intended to generate sufficient data to support a BLA submission, and places wear time into an acceptable clinical hierarchy relative to other study endpoints. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The company anticipates enrolling approximately 300 - 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 year-olds under the Accelerated Approval program is anticipated to be supported by: i. Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and ii. Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in Second Quarter 2025. DBV and FDA are in general agreement that the confirmatory study will need to demonstrate the effectiveness of the Viaskin Peanut patch and will need to be initiated at the time that the BLA is submitted. DBV will prioritize initiation of the COMFORT Toddlers safety study to enable the BLA submission. DBV and the FDA have been engaged in ongoing dialogue regarding the COMFORT Toddlers supplemental safety study in 1 – 3 year-olds with a peanut allergy. The focus of continued exchanges has been on patch adhesion, specifically: The hierarchy of an adhesion assessment within the COMFORT Toddlers study (FDA requesting that it be a study objective vs. exploratory assessment); The sufficiency of adhesion data collected during the EPITOPE study to fully characterize daily patch adhesion duration (wear time) given the EPITOPE adhesion data collection methodology, and, conversely, the collection methodology required to generate sufficient adhesion data to inform the Viaskin label in future studies; and the clinical relevance and regulatory use of adhesion data collected in a study that does not include an efficacy assessment. Viaskin Peanut Patch in Children 4 – 7, In September 2024, DBV announced that patient screening had been completed for the Phase 3 efficacy trial of the Viaskin Peanut patch in peanut allergic children ages 4 – 7 years-old (VITESSE). A total of 654 subjects were enrolled, and DBV anticipates topline data in the fourth quarter of 2025. The COMFORT Children safety study is expected to be initiated in the second quarter of 2025. This study plans to enroll approximately 250 subjects to raise the total number of 4 – 7 year-olds on active treatment across the development program to approximately 600, consistent with prior FDA guidance. These two studies will constitute the core studies for a BLA submission in 4 – 7 year-olds.Price Target Changed • Sep 04Price target decreased by 48% to €2.45Down from €4.73, the current price target is an average from 2 analysts. New target price is 195% above last closing price of €0.83. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.76 last year.Major Estimate Revision • Aug 06Consensus revenue estimates decrease by 18%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$6.49m to US$5.33m. EPS estimate unchanged from -US$1.06 per share at last update. Biotechs industry in France expected to see average net income decline 8.9% next year. Consensus price target of €4.32 unchanged from last update. Share price fell 9.8% to €0.86 over the past week.分析記事 • Aug 04Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue ForecastsOne thing we could say about the analysts on DBV Technologies S.A. ( EPA:DBV ) - they aren't optimistic, having just...Reported Earnings • Jul 31Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.26 loss in 2Q 2023)Second quarter 2024 results: US$0.34 loss per share (further deteriorated from US$0.26 loss in 2Q 2023). Revenue: US$1.16m (down 49% from 2Q 2023). Net loss: US$33.1m (loss widened 37% from 2Q 2023). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.お知らせ • Jul 29DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024DBV Technologies S.A. announced that they will report Q2, 2024 results on Jul 30, 2024New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$95m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$97m net loss in 3 years). Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (€86.1m market cap, or US$93.5m).お知らせ • Jun 20DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)On December 22, 2023, DBV Technologies S.A. (the Company) reported that it had received a letter from the Listing Qualifications Department of the Nasdaq Stock Market on December 20, 2023 regarding the Company’s failure to comply with Nasdaq Continued Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Under Rule 5810(c)(3)(A), the Company automatically was provided a period of 180 calendar days, until June 17, 2024, to regain compliance. On June 18, 2024, the Company was notified by the Listing Qualifications Department that Nasdaq granted the Company’s request to transfer the listing of its American Depositary Shares (“ADSs”) from The Nasdaq Global Select Market tier to The Nasdaq Capital Market tier, and that Nasdaq granted the Company’s request for a second 180-calendar day period, or until December 16, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set in Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the ADSs from The Nasdaq Global Select Market tier to The Nasdaq Capital Market tier will take effect with the open of business on June 20, 2024. The transfer is not expected to impact trading in the ADSs, which will continue to trade on Nasdaq under the symbol “DBVT.” In the event that the Company is not able to cure the bid price deficiency during the Second Compliance Period, Nasdaq will provide written notice that the ADSs will be delisted; however, the Company may request a hearing before the Nasdaq Hearings Panel (the “Panel”), which request, if timely made, would stay any further suspension or delisting action by Nasdaq pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.分析記事 • Jun 14Risks To Shareholder Returns Are Elevated At These Prices For DBV Technologies S.A. (EPA:DBV)It's not a stretch to say that DBV Technologies S.A.'s ( EPA:DBV ) price-to-sales (or "P/S") ratio of 6.8x seems quite...Major Estimate Revision • May 14Consensus EPS estimates upgraded to US$0.74 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$7.02m to US$6.85m. 2024 losses expected to reduce from -US$0.825 to -US$0.74 per share. Biotechs industry in France expected to see average net income growth of 7.7% next year. Consensus price target broadly unchanged at €4.73. Share price was steady at €1.21 over the past week.分析記事 • May 10We Think Shareholders Are Less Likely To Approve A Large Pay Rise For DBV Technologies S.A.'s (EPA:DBV) CEO For NowKey Insights DBV Technologies will host its Annual General Meeting on 16th of May Total pay for CEO Daniel Tass...分析記事 • May 09DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50As you might know, DBV Technologies S.A. ( EPA:DBV ) recently reported its quarterly numbers. Revenues came in at...Price Target Changed • May 09Price target increased by 36% to €6.50Up from €4.78, the current price target is an average from 2 analysts. New target price is 440% above last closing price of €1.20. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$0.74 next year compared to a net loss per share of US$0.76 last year.Reported Earnings • May 08First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: US$0.28 loss per share (further deteriorated from US$0.22 loss in 1Q 2023). Revenue: US$1.41m (down 36% from 1Q 2023). Net loss: US$27.3m (loss widened 33% from 1Q 2023). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 21%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 38% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.New Risk • May 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 14% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$80m free cash flow). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$106m net loss in 3 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).Breakeven Date Change • May 08No longer forecast to breakevenThe 2 analysts covering DBV Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$127.4m in 2026. New consensus forecast suggests the company will make a loss of US$5.71m in 2026.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Mar 25DBV Technologies S.A., Annual General Meeting, May 16, 2024DBV Technologies S.A., Annual General Meeting, May 16, 2024.New Risk • Mar 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$73m Forecast net loss in 3 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$80m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (2.3% increase in shares outstanding).Breakeven Date Change • Mar 14No longer forecast to breakevenThe 3 analysts covering DBV Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$128.7m in 2026. New consensus forecast suggests the company will make a loss of US$119.6m in 2026.分析記事 • Mar 14Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's EstimatesOne thing we could say about the analysts on DBV Technologies S.A. ( EPA:DBV ) - they aren't optimistic, having just...分析記事 • Mar 10DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target PriceDBV Technologies S.A. ( EPA:DBV ) just released its latest annual results and things are looking bullish. Revenue...Reported Earnings • Mar 10Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.77 loss per share (improved from US$1.24 loss in FY 2022). Revenue: US$15.7m (up 225% from FY 2022). Net loss: US$72.7m (loss narrowed 25% from FY 2022). Revenue exceeded analyst estimates by 85%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 35% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 08Price target decreased by 17% to €4.43Down from €5.30, the current price target is an average from 4 analysts. New target price is 212% above last closing price of €1.42. Stock is down 55% over the past year.New Risk • Mar 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$90m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$90m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).お知らせ • Mar 05DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024DBV Technologies S.A. announced that they will report fiscal year 2023 results on Mar 07, 2024Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 3 analysts covering DBV Technologies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$124.0m in 2026. Average annual earnings growth of 48% is required to achieve expected profit on schedule.お知らせ • Dec 22DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn December 20, 2023, DBV Technologies S.A. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that for the last 30 consecutive business days, the bid price of the Company's American Depositary Shares had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's ADSs on the Nasdaq Stock Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until June 17, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's ADSs must be at least $1.00 per share for a minimum of ten consecutive business days before the Compliance Date. If the Company's ADSs do not achieve compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Company intends to actively monitor the closing bid price of its ADSs between now and the Compliance Date and will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price rule.分析記事 • Dec 01Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Nov 03DBV Technologies S.A. to Present New Data at ACAAI 2023DBV Technologies S.A. announced that new data on the use of Viaskin™ Peanut (DBV712) 250 µg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held November 9 – November 13, 2023, in Anaheim, CA. A late-breaking oral abstract has been accepted by the ACAAI and will be presented on the interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) trial of Viaskin™ Peanut in peanut-allergic toddlers. The meeting will also feature a “Product Theater” on Individualizing Peanut Allergy Management: A Case-based Panel Discussion. Drs. Douglas Mack, David Stukus, and Julie Wang will engage in a discussion around the factors influencing peanut allergy management, such as use of food challenges and effects of comorbidities, using various patient scenarios. Viaskin Peanut is the Company’s lead product candidate designed to reduce the risk of allergic reactions due to accidental exposure to peanuts. An investigational, non-invasive, once-daily epicutaneous patch, Viaskin Peanut seeks to deliver microgram quantities of peanut antigen to re-educate the immune system. The safety and efficacy of Viaskin Peanut have not yet been established by the U.S. Food and Drug Administration or the European Medicines Agency.Reported Earnings • Nov 02Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$0.17 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$16.7m (loss narrowed 3.2% from 3Q 2022). Revenue exceeded analyst estimates by 79%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Major Estimate Revision • Nov 02Consensus revenue estimates increase by 29%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$6.30m to US$8.11m. EPS estimate unchanged from -US$0.99 at last update. Biotechs industry in France expected to see average net income growth of 26% next year. Consensus price target of €6.18 unchanged from last update. Share price fell 5.1% to €2.02 over the past week.お知らせ • Oct 28DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023DBV Technologies S.A. announced that they will report Q3, 2023 results on Oct 31, 2023お知らせ • Oct 18DBV Technologies S.A. Announces Executive ChangesOn October 16, 2023, DBV Technologies S.A. announced the appointment of Virginie Boucinha as the Company’s Chief Financial Officer and principal accounting officer, effective as of November 6, 2023. In addition, the Company announced that Sébastien Robitaille, who currently serves as the Company’s Chief Financial Officer, will separate employment with the Company effective November 17, 2023 to pursue other opportunities. Ms. Boucinha, 53, has served as Group Performance Director of the Pierre Fabre Group, a pharmaceutical company, since February 2022. Prior to Pierre Fabre Group, Ms. Boucinha spent over fifteen years through July 2021 with Sanofi, a pharmaceutical manufacturing company, where she served in progressively senior finance and operational leadership roles. In her most recent roles, she was the Global Transformation Office Head from May 2018 to July 2021, where she was a member of the senior leadership team responsible for company structural organization and governance redesign and implementation, and Chief of Staff to the CEO from July 2015 to March 2018, where she handled the chief executive officer and executive committee agenda and coordination, the chief executive officer briefing and strategic projects. Ms. Boucinha is a graduate of Ecole Superieure de Gestion where she obtained a Master of Business Administration.お知らせ • Oct 17DBV Technologies S.A. Appoints Virginie Boucinha as Principal Accounting Officer, Effective as of November 6, 2023On October 16, 2023, DBV Technologies S.A. announced the appointment of Virginie Boucinha as the Company’s Chief Financial Officer and principal accounting officer, effective as of November 6, 2023. In addition, the Company announced that Sébastien Robitaille, who currently serves as the Company’s Chief Financial Officer, will separate employment with the Company effective November 17, 2023 to pursue other opportunities. Ms. Boucinha, 53, has served as Group Performance Director of the Pierre Fabre Group, a pharmaceutical company, since February 2022. Prior to Pierre Fabre Group, Ms. Boucinha spent over fifteen years through July 2021 with Sanofi, a pharmaceutical manufacturing company, where she served in progressively senior finance and operational leadership roles. In her most recent roles, she was the Global Transformation Office Head from May 2018 to July 2021, where she was a member of the senior leadership team responsible for company structural organization and governance redesign and implementation, and Chief of Staff to the CEO from July 2015 to March 2018, where she handled the chief executive officer and executive committee agenda and coordination, the chief executive officer briefing and strategic projects. Ms. Boucinha is a graduate of Ecole Superieure de Gestion where she obtained a Master of Business Administration.お知らせ • Aug 02Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety StudiesDBV Technologies announced the receipt of Written Responses from the FDA on key study design elements for the COMFORT (Characterization of the Optimal Management of FOod Allergy Relief and Treatment) Toddlers and COMFORT Children supplemental safety studies in 1 – 3-year-olds and 4 – 7-year-olds, respectively, with a peanut allergy. The Company also reported financial results for the second quarter and the first half of 2023. The quarterly and half-year financial statements were approved by the Board of Directors on July 28, 2023. Viaskin™ Peanut in 1 – 3-year-olds (original square patch) and Viaskin™ Peanut in 4 – 7-year-olds (modified circular patch) are separate product candidates with independent clinical and regulatory paths supporting two distinct Biologics License Applications (BLAs). DBV received Type C Meeting Written Responses from the FDA on the two supplemental safety studies, known as COMFORT. The COMFORT Toddlers safety study will enroll peanut allergic toddlers ages 1 – 3-years and will support the efficacy results generated from the EPITOPE Phase 3 pivotal study. The COMFORT Children safety study will enroll peanut allergic children ages 4 – 7-years and will support the efficacy results anticipated from the ongoing VITESSE Phase 3 pivotal study. The FDA agreed with a 6-month study duration and a 3:1 randomization (active:placebo) of approximately 400 subjects in the double-blind, placebo-controlled COMFORT Toddlers study. Both COMFORT studies will assess adhesion using the same tools and measurements that were established in VITESSE. Neither the COMFORT Toddlers study nor the COMFORT Children study will require an oral food challenge for participation. The feedback received is consistent with FDA’s position on COMFORT Children in 4 – 7-year-olds, as previously announced in December 2022. Both COMFORT studies aim to bring the total number of subjects on active treatment to approximately 600 participants in each age group, when added to their respective Phase 3 pivotal efficacy studies (i.e., EPITOPE and VITESSE).Reported Earnings • Aug 01Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2022)Second quarter 2023 results: US$0.26 loss per share. Net loss: US$24.2m (loss widened 5.2% from 2Q 2022). Revenue is expected to decline by 2.5% p.a. on average during the next 3 years, while revenues in the Biotechs industry in France are expected to grow by 25%.お知らせ • Jul 26DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023DBV Technologies S.A. announced that they will report first half, 2023 results on Jul 31, 2023New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$34m net loss in 3 years). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Revenue is less than US$5m (US$4.5m revenue).分析記事 • Jun 23Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Major Estimate Revision • May 11Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$4.74m to US$5.61m. Forecast losses expected to reduce from -US$1.08 to -US$0.965 per share. Biotechs industry in France expected to see average net income decline 3.7% next year. Consensus price target of €5.66 unchanged from last update. Share price rose 14% to €3.29 over the past week.Reported Earnings • May 07First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.22 loss per share. Net loss: US$20.6m (loss widened 23% from 1Q 2022). Revenue exceeded analyst estimates by 90%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is expected to decline by 2.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in France are expected to grow by 22%.Major Estimate Revision • Mar 09Consensus revenue estimates decrease by 26%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$6.49m to US$4.79m. EPS estimate unchanged from -US$1.12 per share at last update. Biotechs industry in France expected to see average net income decline 11% next year. Consensus price target of €5.64 unchanged from last update. Share price rose 17% to €3.29 over the past week.分析記事 • Mar 09We're Hopeful That DBV Technologies (EPA:DBV) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Breakeven Date Change • Mar 03The 3 analysts covering DBV Technologies previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 0.8% per year to 2024. The company is expected to make a profit of US$24.8m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.Reported Earnings • Mar 03Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$1.24 loss per share (improved from US$1.78 loss in FY 2021). Net loss: US$96.3m (loss narrowed 1.6% from FY 2021). Revenue missed analyst estimates by 36%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 27% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Price Target Changed • Jan 05Price target increased to €5.64Up from €5.16, the current price target is an average from 4 analysts. New target price is 84% above last closing price of €3.06. Stock is down 0.8% over the past year. The company is forecast to post a net loss per share of US$0.97 next year compared to a net loss per share of US$1.78 last year.Breakeven Date Change • Jan 04Forecast to breakeven in 2025The 2 analysts covering DBV Technologies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$24.9m in 2025. Average annual earnings growth of 55% is required to achieve expected profit on schedule.Price Target Changed • Dec 16Price target decreased to €5.16Down from €5.70, the current price target is an average from 4 analysts. New target price is 101% above last closing price of €2.57. Stock is down 49% over the past year. The company is forecast to post a net loss per share of US$1.11 next year compared to a net loss per share of US$1.78 last year.Reported Earnings • Nov 05Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.18 loss per share (improved from US$0.44 loss in 3Q 2021). Net loss: US$17.3m (loss narrowed 28% from 3Q 2021). Revenue exceeded analyst estimates by 117%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.分析記事 • Oct 04Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Major Estimate Revision • Sep 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.91 to -US$1.07 per share. Revenue forecast unchanged at US$6.78m. Biotechs industry in France expected to see average net income growth of 8.6% next year. Consensus price target of €5.70 unchanged from last update. Share price fell 14% to €3.76 over the past week.Major Estimate Revision • Sep 07Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$7.09m to US$6.72m. Losses expected to increase from US$0.82 per share to US$0.92. Biotechs industry in France expected to see average net income growth of 8.6% next year. Consensus price target of €5.75 unchanged from last update. Share price rose 5.2% to €4.34 over the past week.Major Estimate Revision • Aug 08Consensus revenue estimates increase by 53%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$4.78m to US$7.32m. Forecast losses expected to reduce from -US$1.19 to -US$0.85 per share. Biotechs industry in France expected to see average net income growth of 9.8% next year. Consensus price target up from €4.98 to €5.75. Share price rose 11% to €5.12 over the past week.分析記事 • Aug 06DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value EstimateDoes the August share price for DBV Technologies S.A. ( EPA:DBV ) reflect what it's really worth? Today, we will...Reported Earnings • Aug 02Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$0.35 loss per share (up from US$0.56 loss in 2Q 2021). Net loss: US$23.0m (loss narrowed 25% from 2Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates by 28%. Over the next year, revenue is expected to shrink by 36% compared to a 103% growth forecast for the industry in France. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 10Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$1.41 to -US$1.23 per share. Revenue forecast steady at US$4.98m. Biotechs industry in France expected to see average net income growth of 2.1% next year. Consensus price target of €5.53 unchanged from last update. Share price was steady at €2.50 over the past week.Reported Earnings • May 03First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.30 loss per share (up from US$0.54 loss in 1Q 2021). Net loss: US$16.7m (loss narrowed 43% from 1Q 2021). Revenue exceeded analyst estimates by 106%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 5.4%, compared to a 165% growth forecast for the industry in France. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Scientific Adviser to the CEO & Chairman of Scientific Advisory Board Hugh Sampson was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.分析記事 • Mar 14Here's Why DBV Technologies (EPA:DBV) Must Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Mar 05Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$1.78 loss per share (up from US$2.95 loss in FY 2020). Net loss: US$97.8m (loss narrowed 39% from FY 2020). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) missed analyst estimates by 7.5%. Over the next year, revenue is expected to shrink by 10% compared to a 297% growth forecast for the pharmaceuticals industry in France. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 04No longer forecast to breakevenThe 3 analysts covering DBV Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$27.4m in 2024. New consensus forecast suggests the company will make a loss of US$88.2m in 2024.株主還元DBVFR BiotechsFR 市場7D-6.2%6.8%0.5%1Y90.4%308.7%0.7%株主還元を見る業界別リターン: DBV過去 1 年間で308.7 % の収益を上げたFrench Biotechs業界を下回りました。リターン対市場: DBV過去 1 年間で0.7 % の収益を上げたFrench市場を上回りました。価格変動Is DBV's price volatile compared to industry and market?DBV volatilityDBV Average Weekly Movement7.9%Biotechs Industry Average Movement8.8%Market Average Movement5.4%10% most volatile stocks in FR Market10.6%10% least volatile stocks in FR Market2.9%安定した株価: DBVの株価は、 French市場と比較して過去 3 か月間で変動しています。時間の経過による変動: DBVの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてFrenchの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2002126Daniel Tasséwww.dbv-technologies.comDBV Technologies S.A.は臨床段階にあるバイオ医薬品会社で、経皮免疫療法製品の研究開発に従事している。同社の製品パイプラインには、ピーナッツアレルギーの治療薬として第3相臨床試験を終了した免疫療法製品Viaskin Peanutと、免疫グロブリンE（IgE）介在性または牛乳タンパク質アレルギーおよび好酸球性食道炎の治療薬として第1/2相臨床試験中のViaskin Milkがある。同社の初期段階の研究プログラムには、呼吸器合胞体ウイルスのワクチン、炎症性腸疾患、セリアック病、I型糖尿病の潜在的治療薬などがある。さらに、食物アレルギーを治療する可能性のあるViaskin技術プラットフォームを開発している。また、ネスレ・ヘルスサイエンス社との提携により、乳幼児の非IgE介在性CMPA診断のための、すぐに使えるアトピーパッチテストMAG1Cを開発している。DBV Technologies S.A.は2002年に設立され、フランスのシャティヨンに本社を置いている。もっと見るDBV Technologies S.A. 基礎のまとめDBV Technologies の収益と売上を時価総額と比較するとどうか。DBV 基礎統計学時価総額€994.27m収益（TTM）-€142.33m売上高(TTM)€4.88m206.6xP/Sレシオ-7.1xPER（株価収益率DBV は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計DBV 損益計算書（TTM）収益US$5.74m売上原価US$0売上総利益US$5.74mその他の費用US$173.18m収益-US$167.45m直近の収益報告Mar 31, 2026次回決算日Jul 29, 2026一株当たり利益（EPS）-0.57グロス・マージン100.00%純利益率-2,919.23%有利子負債／自己資本比率0%DBV の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 11:29終値2026/05/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DBV Technologies S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Tazeen AhmadBofA Global ResearchKristen KluskaCantor Fitzgerald & Co.Jonathan WollebenCitizens JMP Securities, LLC13 その他のアナリストを表示
Featured narrative•Pharmaceuticals & Biotech opportunityUnicycive Therapeutics4 months ago author updated this narrativeSTFair Value from stuart_robertsUS$21.5363.5% 割安 内在価値ディスカウントLooking to be second time lucky with a game-changing new productKey Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read full narrative6.4kusers have viewed this narrative18users have liked this narrative0users have commented on this narrative130users have followed this narrativeRead narrative
ライブニュース • May 06DBV Technologies Prepares VIASKIN Peanut Regulatory Filings With Expanded Cash Position and New Clinical TrialDBV Technologies reported a Q1 2026 net loss of US$47.6 million as it funds development and regulatory work for its VIASKIN Peanut patch. The company plans to submit two Biologics License Applications in 2026 for children aged 4 to 7 years and toddlers aged 1 to 3 years, and to launch a new Phase 2 THRIVE trial in infants aged 6 to 12 months. An amended 10-K/A and related 8-K detailed expanded governance disclosures, a large PIPE financing completed in 2025 to 2026, and new performance-based share units granted to the CEO tied to FDA progress on VIASKIN Peanut. For you as an investor, the picture is of a company spending heavily to move from pure clinical development toward potential commercialization of a single lead program. The widened Q1 2026 loss reflects higher research, development and commercial infrastructure costs, while the cash and cash equivalents position of US$229 million, supported by about US$386.2 million of equity and warrant funding since March 2025, is described as sufficient to fund operations into Q2 2027. That timeline would give DBV a period to progress its regulatory filings and clinical work without an immediate need for more capital, based on current plans. The governance and compensation disclosures matter because they show how leadership is being incentivized. The CEO’s 1,740,000 performance share units vest only if the FDA accepts the VIASKIN Peanut BLAs and if he remains in the role through mid 2028, which aligns management rewards with key regulatory milestones. Investors may want to track the timing and outcome of the planned BLA submissions, the progress of the THRIVE infant study, and any updates on cash usage against the stated funding runway.
Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 54% growth forecast for the Biotechs industry in France.
お知らせ • May 01DBV Technologies S.A., Annual General Meeting, Jun 03, 2026DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon France
お知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026
Reported Earnings • Mar 29Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 24%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 49% growth forecast for the Biotechs industry in France.
Breakeven Date Change • Mar 29Forecast to breakeven in 2028The 5 analysts covering DBV Technologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 20% per year to 2027. The company is expected to make a profit of US$86.5m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
ライブニュース • May 06DBV Technologies Prepares VIASKIN Peanut Regulatory Filings With Expanded Cash Position and New Clinical TrialDBV Technologies reported a Q1 2026 net loss of US$47.6 million as it funds development and regulatory work for its VIASKIN Peanut patch. The company plans to submit two Biologics License Applications in 2026 for children aged 4 to 7 years and toddlers aged 1 to 3 years, and to launch a new Phase 2 THRIVE trial in infants aged 6 to 12 months. An amended 10-K/A and related 8-K detailed expanded governance disclosures, a large PIPE financing completed in 2025 to 2026, and new performance-based share units granted to the CEO tied to FDA progress on VIASKIN Peanut. For you as an investor, the picture is of a company spending heavily to move from pure clinical development toward potential commercialization of a single lead program. The widened Q1 2026 loss reflects higher research, development and commercial infrastructure costs, while the cash and cash equivalents position of US$229 million, supported by about US$386.2 million of equity and warrant funding since March 2025, is described as sufficient to fund operations into Q2 2027. That timeline would give DBV a period to progress its regulatory filings and clinical work without an immediate need for more capital, based on current plans. The governance and compensation disclosures matter because they show how leadership is being incentivized. The CEO’s 1,740,000 performance share units vest only if the FDA accepts the VIASKIN Peanut BLAs and if he remains in the role through mid 2028, which aligns management rewards with key regulatory milestones. Investors may want to track the timing and outcome of the planned BLA submissions, the progress of the THRIVE infant study, and any updates on cash usage against the stated funding runway.
Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 54% growth forecast for the Biotechs industry in France.
お知らせ • May 01DBV Technologies S.A., Annual General Meeting, Jun 03, 2026DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon France
お知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026
Reported Earnings • Mar 29Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 24%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 49% growth forecast for the Biotechs industry in France.
Breakeven Date Change • Mar 29Forecast to breakeven in 2028The 5 analysts covering DBV Technologies expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 20% per year to 2027. The company is expected to make a profit of US$86.5m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
お知らせ • Mar 02Dbv Technologies Highlights Additional Data from Successful Phase 3 Vitesse Study At the Aaaai 2026 Annual MeetingDBV Technologies announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV's VIASKIN®? Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years. The VITESSE study met its primary endpoint whereby VIASKIN®?Peanut demonstrated a statistically significant treatment effect (pp. The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period. These results not only support the VIASKIN®? peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population.
Price Target Changed • Dec 22Price target increased by 116% to €3.29Up from €1.52, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €3.43. Stock is up 446% over the past year. The company is forecast to post a net loss per share of US$1.05 next year compared to a net loss per share of US$1.17 last year.
Major Estimate Revision • Dec 17Consensus revenue estimates decrease by 10%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$7.00m to US$6.26m. EPS estimate unchanged from -US$1.05 per share at last update. Biotechs industry in France expected to see average net income growth of 34% next year. Consensus price target of €1.56 unchanged from last update. Share price rose 11% to €3.68 over the past week.
分析記事 • Dec 09Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, DBV Technologies...
Major Estimate Revision • Nov 07Consensus revenue estimates decrease by 14%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$7.78m to US$6.69m. EPS estimate increased from -US$1.27 to -US$1.05 per share. Biotechs industry in France expected to see average net income growth of 25% next year. Consensus price target up from €1.52 to €1.56. Share price fell 5.5% to €2.48 over the past week.
お知らせ • Nov 04DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial, Effective November 3, 2025DBV Technologies announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin(R) Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year. Kevin Trapp is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical industry. Before rejoining DBV, Kevin served as a consultant to the Company in his most recent role as Managing Director at Biotech Value Advisors (BVA) where he advised biotechnology boards of directors and executive leadership with product strategy, launch planning, and business evaluation. He built his career at Bristol-Myers Squibb (BMS), where he held roles of increasing responsibility across finance, sales, marketing, and general management. During his time at BMS, he managed a ~$4 billion U.S. specialty and primary care portfolio and was a key stakeholder in the planning and subsequent launches of more than 10 products and indications - including Abilify(R), Atripla(R), Reyataz(R), Orencia(R), and Daklinza(R). Mr. Trapp earned a bachelor's degree from the University of Connecticut School of Business and completed the General Management Program from the European Centre for Executive Development (CEDEP) at INSEAD.
New Risk • Oct 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$98m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$98m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$81m net loss in 3 years).
お知らせ • Sep 19DBV Technologies Announces Resignation of Daniel Soland as a Member of its Board of Directors, Effective September 18, 2025DBV Technologies announced the resignation of Daniel Soland, as a member of its Board of Directors, effective September 18, 2025.
お知らせ • Sep 06DBV Technologies S.A. has filed a Follow-on Equity Offering in the amount of $150 million.DBV Technologies S.A. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Transaction Features: At the Market Offering
Major Estimate Revision • Aug 13Consensus EPS estimates upgraded to US$0.86 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -US$1.17 to -US$0.86 per share. Revenue forecast steady at US$4.03m. Biotechs industry in France expected to see average net income growth of 7.2% next year. Consensus price target of €1.52 unchanged from last update. Share price was steady at €1.69 over the past week.
Major Estimate Revision • Aug 05Consensus revenue estimates increase by 33%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$2.98m to US$3.98m. EPS estimate unchanged from -US$1.17 at last update. Biotechs industry in France expected to see average net income growth of 7.2% next year. Consensus price target of €1.52 unchanged from last update. Share price fell 4.6% to €1.63 over the past week.
Reported Earnings • Jul 30Second quarter 2025 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2024)Second quarter 2025 results: US$0.31 loss per share. Net loss: US$41.9m (loss widened 26% from 2Q 2024). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in France.
お知らせ • Jul 23DBV Technologies S.A. Announces Executive ChangesDBV Technologies S.A. announced the appointment of James Briggs as its Chief Human Resources Officer, succeeding Caroline Daniere. An experienced human capital executive, James will lead key initiatives as DBV transitions from a development-stage biotechnology company to a potential commercial organization. Mr. Briggs will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. Most recently, Mr. Briggs served as Partner at East Bay Human Capital, a human resources consulting firm specializing in human capital strategy, change management, and organizational design. Previously, he held several executive roles, including Chief Executive Officer at MNG Health, where he led the successful turnaround and sale of the healthcare technology company. He also served as Chief Human Resources Officer at multiple organizations, including Ciox Health and Ikaria Inc. Mr. Briggs holds a Master's degree in Human Relations and a Bachelor's degree in Communications from the University of Illinois at Urbana-Champaign. He is a certified Senior Professional in Human Resources (SPHR) and a Six Sigma Green Belt.
Price Target Changed • Jul 01Price target decreased by 38% to €1.52Down from €2.46, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €1.56. Stock is up 96% over the past year. The company is forecast to post a net loss per share of US$1.17 next year compared to a net loss per share of US$1.17 last year.
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jun 26DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 - 3 Years OldDBV Technologies provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin®? Peanut patch 250 mg in peanut-allergic children ages 1 - 3 years old. COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 - 90 study centers across the U.S., Canada, Australia, UK and Europe. COMFORT Toddlers is a Phase 3 double-blind, placebo-controlled (DBPC) safety study designed to supplement the safety and efficacy data from the completed Phase 3 EPITOPE study in the same population. The study duration will be six months followed by an optional 18-month open-label treatment phase, to generate up to 24 or 18 months of active treatment with the Viaskin Peanut patch for participants randomized to the active or placebo groups, respectively.
お知らせ • May 06DBV Technologies S.A., Annual General Meeting, Jun 11, 2025DBV Technologies S.A., Annual General Meeting, Jun 11, 2025. Location: 107 avenue de la republique 92320 chatillon, France
お知らせ • Apr 01DBV Technologies S.A. announced delayed annual 10-K filingOn 03/31/2025, DBV Technologies S.A. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Reported Earnings • Mar 24Full year 2024 earnings released: US$1.17 loss per share (vs US$0.77 loss in FY 2023)Full year 2024 results: US$1.17 loss per share (further deteriorated from US$0.77 loss in FY 2023). Net loss: US$113.9m (loss widened 57% from FY 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
分析記事 • Jan 10Revenues Not Telling The Story For DBV Technologies S.A. (EPA:DBV) After Shares Rise 76%DBV Technologies S.A. ( EPA:DBV ) shareholders have had their patience rewarded with a 76% share price jump in the last...
New Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$109m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$115m net loss in 3 years). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Market cap is less than US$100m (€67.0m market cap, or US$68.9m).
お知らせ • Dec 17DBV Technologies Regains Compliance with Nasdaq Listing Rule 5550(a)(2)On December 13, 2024, DBV Technologies S.A. (the Company") received a letter from the Listing Qualifications Staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). The Staff determined that for 10 consecutive business days, from November 29, 2024 to December 12, 2024, the closing bid price of the Company's American Depositary Shares has been at $1.00 per share or greater.
お知らせ • Nov 12DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain ComplianceDBV Technologies S.A. announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to five (5) ordinary shares (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about November 29, 2024 (the “Effective Date”). For the Company’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-five reverse ADS split and is intended to enable the Company to regain compliance with the Nasdaq minimum bid price requirement.
Reported Earnings • Nov 08Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023)Third quarter 2024 results: US$0.32 loss per share (further deteriorated from US$0.17 loss in 3Q 2023). Revenue: US$1.07m (down 55% from 3Q 2023). Net loss: US$30.4m (loss widened 82% from 3Q 2023). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 31% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
分析記事 • Oct 24DBV Technologies S.A.'s (EPA:DBV) 41% Share Price Surge Not Quite Adding UpDBV Technologies S.A. ( EPA:DBV ) shareholders would be excited to see that the share price has had a great month...
New Risk • Oct 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 5.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$105m free cash flow). Earnings are forecast to decline by an average of 5.2% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$117m net loss in 3 years). Market cap is less than US$100m (€69.6m market cap, or US$75.0m).
お知らせ • Oct 23Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and EuropeDBV Technologies announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe. DBV intends to formalize the Accelerated Approval guidance provided by the FDA via submission of a meeting request. Viaskin Peanut Patch in Toddlers 1 – 3 Years. Accelerated Approval Pathway, FDA guidance for Accelerated Approval include three qualifying criteria: 1) that the product treats a serious condition, 2) that the product candidate generally provides a meaningful advantage over available therapies, and 3) that the product candidate demonstrates an effect on an intermediate clinical endpoint that is reasonably likely to predict clinical benefit. FDA confirmed that DBV has met criterion 1 and 2. Regarding criterion 3, FDA has provided guidance and suggestion regarding the intermediate clinical endpoint, which DBV has agreed to in informal discussions with the FDA. DBV intends to formalize the Accelerated Approval guidance provided by FDA via submission of a meeting request to confirm the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including the third Accelerated Approval criterion regarding the intermediate clinical endpoint. DBV expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if Viaskin Peanut is approved. COMFORT Toddlers DBV is pleased to have aligned with FDA on a wear time collection methodology in COMFORT Toddlers that provides a practical approach for subjects and families, is intended to generate sufficient data to support a BLA submission, and places wear time into an acceptable clinical hierarchy relative to other study endpoints. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The company anticipates enrolling approximately 300 - 350 subjects on active treatment into the safety study, which would bring the total Viaskin Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 year-olds under the Accelerated Approval program is anticipated to be supported by: i. Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and ii. Additional safety data generated in COMFORT Toddlers supplemental safety study to be initiated in Second Quarter 2025. DBV and FDA are in general agreement that the confirmatory study will need to demonstrate the effectiveness of the Viaskin Peanut patch and will need to be initiated at the time that the BLA is submitted. DBV will prioritize initiation of the COMFORT Toddlers safety study to enable the BLA submission. DBV and the FDA have been engaged in ongoing dialogue regarding the COMFORT Toddlers supplemental safety study in 1 – 3 year-olds with a peanut allergy. The focus of continued exchanges has been on patch adhesion, specifically: The hierarchy of an adhesion assessment within the COMFORT Toddlers study (FDA requesting that it be a study objective vs. exploratory assessment); The sufficiency of adhesion data collected during the EPITOPE study to fully characterize daily patch adhesion duration (wear time) given the EPITOPE adhesion data collection methodology, and, conversely, the collection methodology required to generate sufficient adhesion data to inform the Viaskin label in future studies; and the clinical relevance and regulatory use of adhesion data collected in a study that does not include an efficacy assessment. Viaskin Peanut Patch in Children 4 – 7, In September 2024, DBV announced that patient screening had been completed for the Phase 3 efficacy trial of the Viaskin Peanut patch in peanut allergic children ages 4 – 7 years-old (VITESSE). A total of 654 subjects were enrolled, and DBV anticipates topline data in the fourth quarter of 2025. The COMFORT Children safety study is expected to be initiated in the second quarter of 2025. This study plans to enroll approximately 250 subjects to raise the total number of 4 – 7 year-olds on active treatment across the development program to approximately 600, consistent with prior FDA guidance. These two studies will constitute the core studies for a BLA submission in 4 – 7 year-olds.
Price Target Changed • Sep 04Price target decreased by 48% to €2.45Down from €4.73, the current price target is an average from 2 analysts. New target price is 195% above last closing price of €0.83. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.76 last year.
Major Estimate Revision • Aug 06Consensus revenue estimates decrease by 18%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$6.49m to US$5.33m. EPS estimate unchanged from -US$1.06 per share at last update. Biotechs industry in France expected to see average net income decline 8.9% next year. Consensus price target of €4.32 unchanged from last update. Share price fell 9.8% to €0.86 over the past week.
分析記事 • Aug 04Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue ForecastsOne thing we could say about the analysts on DBV Technologies S.A. ( EPA:DBV ) - they aren't optimistic, having just...
Reported Earnings • Jul 31Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.26 loss in 2Q 2023)Second quarter 2024 results: US$0.34 loss per share (further deteriorated from US$0.26 loss in 2Q 2023). Revenue: US$1.16m (down 49% from 2Q 2023). Net loss: US$33.1m (loss widened 37% from 2Q 2023). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
お知らせ • Jul 29DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024DBV Technologies S.A. announced that they will report Q2, 2024 results on Jul 30, 2024
New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$95m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$97m net loss in 3 years). Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (€86.1m market cap, or US$93.5m).
お知らせ • Jun 20DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)On December 22, 2023, DBV Technologies S.A. (the Company) reported that it had received a letter from the Listing Qualifications Department of the Nasdaq Stock Market on December 20, 2023 regarding the Company’s failure to comply with Nasdaq Continued Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Under Rule 5810(c)(3)(A), the Company automatically was provided a period of 180 calendar days, until June 17, 2024, to regain compliance. On June 18, 2024, the Company was notified by the Listing Qualifications Department that Nasdaq granted the Company’s request to transfer the listing of its American Depositary Shares (“ADSs”) from The Nasdaq Global Select Market tier to The Nasdaq Capital Market tier, and that Nasdaq granted the Company’s request for a second 180-calendar day period, or until December 16, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set in Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the ADSs from The Nasdaq Global Select Market tier to The Nasdaq Capital Market tier will take effect with the open of business on June 20, 2024. The transfer is not expected to impact trading in the ADSs, which will continue to trade on Nasdaq under the symbol “DBVT.” In the event that the Company is not able to cure the bid price deficiency during the Second Compliance Period, Nasdaq will provide written notice that the ADSs will be delisted; however, the Company may request a hearing before the Nasdaq Hearings Panel (the “Panel”), which request, if timely made, would stay any further suspension or delisting action by Nasdaq pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.
分析記事 • Jun 14Risks To Shareholder Returns Are Elevated At These Prices For DBV Technologies S.A. (EPA:DBV)It's not a stretch to say that DBV Technologies S.A.'s ( EPA:DBV ) price-to-sales (or "P/S") ratio of 6.8x seems quite...
Major Estimate Revision • May 14Consensus EPS estimates upgraded to US$0.74 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$7.02m to US$6.85m. 2024 losses expected to reduce from -US$0.825 to -US$0.74 per share. Biotechs industry in France expected to see average net income growth of 7.7% next year. Consensus price target broadly unchanged at €4.73. Share price was steady at €1.21 over the past week.
分析記事 • May 10We Think Shareholders Are Less Likely To Approve A Large Pay Rise For DBV Technologies S.A.'s (EPA:DBV) CEO For NowKey Insights DBV Technologies will host its Annual General Meeting on 16th of May Total pay for CEO Daniel Tass...
分析記事 • May 09DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50As you might know, DBV Technologies S.A. ( EPA:DBV ) recently reported its quarterly numbers. Revenues came in at...
Price Target Changed • May 09Price target increased by 36% to €6.50Up from €4.78, the current price target is an average from 2 analysts. New target price is 440% above last closing price of €1.20. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$0.74 next year compared to a net loss per share of US$0.76 last year.
Reported Earnings • May 08First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: US$0.28 loss per share (further deteriorated from US$0.22 loss in 1Q 2023). Revenue: US$1.41m (down 36% from 1Q 2023). Net loss: US$27.3m (loss widened 33% from 1Q 2023). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 21%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 38% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
New Risk • May 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 14% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$80m free cash flow). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$106m net loss in 3 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
Breakeven Date Change • May 08No longer forecast to breakevenThe 2 analysts covering DBV Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$127.4m in 2026. New consensus forecast suggests the company will make a loss of US$5.71m in 2026.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Mar 25DBV Technologies S.A., Annual General Meeting, May 16, 2024DBV Technologies S.A., Annual General Meeting, May 16, 2024.
New Risk • Mar 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$73m Forecast net loss in 3 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$80m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (2.3% increase in shares outstanding).
Breakeven Date Change • Mar 14No longer forecast to breakevenThe 3 analysts covering DBV Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$128.7m in 2026. New consensus forecast suggests the company will make a loss of US$119.6m in 2026.
分析記事 • Mar 14Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's EstimatesOne thing we could say about the analysts on DBV Technologies S.A. ( EPA:DBV ) - they aren't optimistic, having just...
分析記事 • Mar 10DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target PriceDBV Technologies S.A. ( EPA:DBV ) just released its latest annual results and things are looking bullish. Revenue...
Reported Earnings • Mar 10Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.77 loss per share (improved from US$1.24 loss in FY 2022). Revenue: US$15.7m (up 225% from FY 2022). Net loss: US$72.7m (loss narrowed 25% from FY 2022). Revenue exceeded analyst estimates by 85%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 35% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 08Price target decreased by 17% to €4.43Down from €5.30, the current price target is an average from 4 analysts. New target price is 212% above last closing price of €1.42. Stock is down 55% over the past year.
New Risk • Mar 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$90m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$90m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
お知らせ • Mar 05DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024DBV Technologies S.A. announced that they will report fiscal year 2023 results on Mar 07, 2024
Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 3 analysts covering DBV Technologies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$124.0m in 2026. Average annual earnings growth of 48% is required to achieve expected profit on schedule.
お知らせ • Dec 22DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn December 20, 2023, DBV Technologies S.A. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that for the last 30 consecutive business days, the bid price of the Company's American Depositary Shares had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's ADSs on the Nasdaq Stock Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until June 17, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's ADSs must be at least $1.00 per share for a minimum of ten consecutive business days before the Compliance Date. If the Company's ADSs do not achieve compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Company intends to actively monitor the closing bid price of its ADSs between now and the Compliance Date and will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price rule.
分析記事 • Dec 01Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Nov 03DBV Technologies S.A. to Present New Data at ACAAI 2023DBV Technologies S.A. announced that new data on the use of Viaskin™ Peanut (DBV712) 250 µg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held November 9 – November 13, 2023, in Anaheim, CA. A late-breaking oral abstract has been accepted by the ACAAI and will be presented on the interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) trial of Viaskin™ Peanut in peanut-allergic toddlers. The meeting will also feature a “Product Theater” on Individualizing Peanut Allergy Management: A Case-based Panel Discussion. Drs. Douglas Mack, David Stukus, and Julie Wang will engage in a discussion around the factors influencing peanut allergy management, such as use of food challenges and effects of comorbidities, using various patient scenarios. Viaskin Peanut is the Company’s lead product candidate designed to reduce the risk of allergic reactions due to accidental exposure to peanuts. An investigational, non-invasive, once-daily epicutaneous patch, Viaskin Peanut seeks to deliver microgram quantities of peanut antigen to re-educate the immune system. The safety and efficacy of Viaskin Peanut have not yet been established by the U.S. Food and Drug Administration or the European Medicines Agency.
Reported Earnings • Nov 02Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$0.17 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$16.7m (loss narrowed 3.2% from 3Q 2022). Revenue exceeded analyst estimates by 79%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Nov 02Consensus revenue estimates increase by 29%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$6.30m to US$8.11m. EPS estimate unchanged from -US$0.99 at last update. Biotechs industry in France expected to see average net income growth of 26% next year. Consensus price target of €6.18 unchanged from last update. Share price fell 5.1% to €2.02 over the past week.
お知らせ • Oct 28DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023DBV Technologies S.A. announced that they will report Q3, 2023 results on Oct 31, 2023
お知らせ • Oct 18DBV Technologies S.A. Announces Executive ChangesOn October 16, 2023, DBV Technologies S.A. announced the appointment of Virginie Boucinha as the Company’s Chief Financial Officer and principal accounting officer, effective as of November 6, 2023. In addition, the Company announced that Sébastien Robitaille, who currently serves as the Company’s Chief Financial Officer, will separate employment with the Company effective November 17, 2023 to pursue other opportunities. Ms. Boucinha, 53, has served as Group Performance Director of the Pierre Fabre Group, a pharmaceutical company, since February 2022. Prior to Pierre Fabre Group, Ms. Boucinha spent over fifteen years through July 2021 with Sanofi, a pharmaceutical manufacturing company, where she served in progressively senior finance and operational leadership roles. In her most recent roles, she was the Global Transformation Office Head from May 2018 to July 2021, where she was a member of the senior leadership team responsible for company structural organization and governance redesign and implementation, and Chief of Staff to the CEO from July 2015 to March 2018, where she handled the chief executive officer and executive committee agenda and coordination, the chief executive officer briefing and strategic projects. Ms. Boucinha is a graduate of Ecole Superieure de Gestion where she obtained a Master of Business Administration.
お知らせ • Oct 17DBV Technologies S.A. Appoints Virginie Boucinha as Principal Accounting Officer, Effective as of November 6, 2023On October 16, 2023, DBV Technologies S.A. announced the appointment of Virginie Boucinha as the Company’s Chief Financial Officer and principal accounting officer, effective as of November 6, 2023. In addition, the Company announced that Sébastien Robitaille, who currently serves as the Company’s Chief Financial Officer, will separate employment with the Company effective November 17, 2023 to pursue other opportunities. Ms. Boucinha, 53, has served as Group Performance Director of the Pierre Fabre Group, a pharmaceutical company, since February 2022. Prior to Pierre Fabre Group, Ms. Boucinha spent over fifteen years through July 2021 with Sanofi, a pharmaceutical manufacturing company, where she served in progressively senior finance and operational leadership roles. In her most recent roles, she was the Global Transformation Office Head from May 2018 to July 2021, where she was a member of the senior leadership team responsible for company structural organization and governance redesign and implementation, and Chief of Staff to the CEO from July 2015 to March 2018, where she handled the chief executive officer and executive committee agenda and coordination, the chief executive officer briefing and strategic projects. Ms. Boucinha is a graduate of Ecole Superieure de Gestion where she obtained a Master of Business Administration.
お知らせ • Aug 02Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety StudiesDBV Technologies announced the receipt of Written Responses from the FDA on key study design elements for the COMFORT (Characterization of the Optimal Management of FOod Allergy Relief and Treatment) Toddlers and COMFORT Children supplemental safety studies in 1 – 3-year-olds and 4 – 7-year-olds, respectively, with a peanut allergy. The Company also reported financial results for the second quarter and the first half of 2023. The quarterly and half-year financial statements were approved by the Board of Directors on July 28, 2023. Viaskin™ Peanut in 1 – 3-year-olds (original square patch) and Viaskin™ Peanut in 4 – 7-year-olds (modified circular patch) are separate product candidates with independent clinical and regulatory paths supporting two distinct Biologics License Applications (BLAs). DBV received Type C Meeting Written Responses from the FDA on the two supplemental safety studies, known as COMFORT. The COMFORT Toddlers safety study will enroll peanut allergic toddlers ages 1 – 3-years and will support the efficacy results generated from the EPITOPE Phase 3 pivotal study. The COMFORT Children safety study will enroll peanut allergic children ages 4 – 7-years and will support the efficacy results anticipated from the ongoing VITESSE Phase 3 pivotal study. The FDA agreed with a 6-month study duration and a 3:1 randomization (active:placebo) of approximately 400 subjects in the double-blind, placebo-controlled COMFORT Toddlers study. Both COMFORT studies will assess adhesion using the same tools and measurements that were established in VITESSE. Neither the COMFORT Toddlers study nor the COMFORT Children study will require an oral food challenge for participation. The feedback received is consistent with FDA’s position on COMFORT Children in 4 – 7-year-olds, as previously announced in December 2022. Both COMFORT studies aim to bring the total number of subjects on active treatment to approximately 600 participants in each age group, when added to their respective Phase 3 pivotal efficacy studies (i.e., EPITOPE and VITESSE).
Reported Earnings • Aug 01Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2022)Second quarter 2023 results: US$0.26 loss per share. Net loss: US$24.2m (loss widened 5.2% from 2Q 2022). Revenue is expected to decline by 2.5% p.a. on average during the next 3 years, while revenues in the Biotechs industry in France are expected to grow by 25%.
お知らせ • Jul 26DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023DBV Technologies S.A. announced that they will report first half, 2023 results on Jul 31, 2023
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$34m net loss in 3 years). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Revenue is less than US$5m (US$4.5m revenue).
分析記事 • Jun 23Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Major Estimate Revision • May 11Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$4.74m to US$5.61m. Forecast losses expected to reduce from -US$1.08 to -US$0.965 per share. Biotechs industry in France expected to see average net income decline 3.7% next year. Consensus price target of €5.66 unchanged from last update. Share price rose 14% to €3.29 over the past week.
Reported Earnings • May 07First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.22 loss per share. Net loss: US$20.6m (loss widened 23% from 1Q 2022). Revenue exceeded analyst estimates by 90%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is expected to decline by 2.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in France are expected to grow by 22%.
Major Estimate Revision • Mar 09Consensus revenue estimates decrease by 26%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$6.49m to US$4.79m. EPS estimate unchanged from -US$1.12 per share at last update. Biotechs industry in France expected to see average net income decline 11% next year. Consensus price target of €5.64 unchanged from last update. Share price rose 17% to €3.29 over the past week.
分析記事 • Mar 09We're Hopeful That DBV Technologies (EPA:DBV) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Breakeven Date Change • Mar 03The 3 analysts covering DBV Technologies previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 0.8% per year to 2024. The company is expected to make a profit of US$24.8m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
Reported Earnings • Mar 03Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$1.24 loss per share (improved from US$1.78 loss in FY 2021). Net loss: US$96.3m (loss narrowed 1.6% from FY 2021). Revenue missed analyst estimates by 36%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 27% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Price Target Changed • Jan 05Price target increased to €5.64Up from €5.16, the current price target is an average from 4 analysts. New target price is 84% above last closing price of €3.06. Stock is down 0.8% over the past year. The company is forecast to post a net loss per share of US$0.97 next year compared to a net loss per share of US$1.78 last year.
Breakeven Date Change • Jan 04Forecast to breakeven in 2025The 2 analysts covering DBV Technologies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$24.9m in 2025. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
Price Target Changed • Dec 16Price target decreased to €5.16Down from €5.70, the current price target is an average from 4 analysts. New target price is 101% above last closing price of €2.57. Stock is down 49% over the past year. The company is forecast to post a net loss per share of US$1.11 next year compared to a net loss per share of US$1.78 last year.
Reported Earnings • Nov 05Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.18 loss per share (improved from US$0.44 loss in 3Q 2021). Net loss: US$17.3m (loss narrowed 28% from 3Q 2021). Revenue exceeded analyst estimates by 117%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
分析記事 • Oct 04Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Major Estimate Revision • Sep 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.91 to -US$1.07 per share. Revenue forecast unchanged at US$6.78m. Biotechs industry in France expected to see average net income growth of 8.6% next year. Consensus price target of €5.70 unchanged from last update. Share price fell 14% to €3.76 over the past week.
Major Estimate Revision • Sep 07Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$7.09m to US$6.72m. Losses expected to increase from US$0.82 per share to US$0.92. Biotechs industry in France expected to see average net income growth of 8.6% next year. Consensus price target of €5.75 unchanged from last update. Share price rose 5.2% to €4.34 over the past week.
Major Estimate Revision • Aug 08Consensus revenue estimates increase by 53%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$4.78m to US$7.32m. Forecast losses expected to reduce from -US$1.19 to -US$0.85 per share. Biotechs industry in France expected to see average net income growth of 9.8% next year. Consensus price target up from €4.98 to €5.75. Share price rose 11% to €5.12 over the past week.
分析記事 • Aug 06DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value EstimateDoes the August share price for DBV Technologies S.A. ( EPA:DBV ) reflect what it's really worth? Today, we will...
Reported Earnings • Aug 02Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$0.35 loss per share (up from US$0.56 loss in 2Q 2021). Net loss: US$23.0m (loss narrowed 25% from 2Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates by 28%. Over the next year, revenue is expected to shrink by 36% compared to a 103% growth forecast for the industry in France. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 10Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$1.41 to -US$1.23 per share. Revenue forecast steady at US$4.98m. Biotechs industry in France expected to see average net income growth of 2.1% next year. Consensus price target of €5.53 unchanged from last update. Share price was steady at €2.50 over the past week.
Reported Earnings • May 03First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.30 loss per share (up from US$0.54 loss in 1Q 2021). Net loss: US$16.7m (loss narrowed 43% from 1Q 2021). Revenue exceeded analyst estimates by 106%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 5.4%, compared to a 165% growth forecast for the industry in France. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Scientific Adviser to the CEO & Chairman of Scientific Advisory Board Hugh Sampson was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Mar 14Here's Why DBV Technologies (EPA:DBV) Must Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Mar 05Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$1.78 loss per share (up from US$2.95 loss in FY 2020). Net loss: US$97.8m (loss narrowed 39% from FY 2020). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) missed analyst estimates by 7.5%. Over the next year, revenue is expected to shrink by 10% compared to a 297% growth forecast for the pharmaceuticals industry in France. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 04No longer forecast to breakevenThe 3 analysts covering DBV Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$27.4m in 2024. New consensus forecast suggests the company will make a loss of US$88.2m in 2024.
